JP2005508165A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508165A5
JP2005508165A5 JP2003534444A JP2003534444A JP2005508165A5 JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acids
polynucleotide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003534444A
Other languages
English (en)
Japanese (ja)
Other versions
JP4383869B2 (ja
JP2005508165A (ja
Filing date
Publication date
Priority claimed from US09/972,599 external-priority patent/US7119165B2/en
Application filed filed Critical
Publication of JP2005508165A publication Critical patent/JP2005508165A/ja
Publication of JP2005508165A5 publication Critical patent/JP2005508165A5/ja
Application granted granted Critical
Publication of JP4383869B2 publication Critical patent/JP4383869B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003534444A 2001-10-06 2002-10-04 軸索成長のnogoのレセプターを仲介とした妨害 Expired - Fee Related JP4383869B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/972,599 US7119165B2 (en) 2000-01-12 2001-10-06 Nogo receptor-mediated blockade of axonal growth
PCT/US2002/032007 WO2003031462A2 (en) 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth

Publications (3)

Publication Number Publication Date
JP2005508165A JP2005508165A (ja) 2005-03-31
JP2005508165A5 true JP2005508165A5 (enExample) 2006-01-05
JP4383869B2 JP4383869B2 (ja) 2009-12-16

Family

ID=25519870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003534444A Expired - Fee Related JP4383869B2 (ja) 2001-10-06 2002-10-04 軸索成長のnogoのレセプターを仲介とした妨害

Country Status (6)

Country Link
US (6) US7119165B2 (enExample)
EP (1) EP1451337A4 (enExample)
JP (1) JP4383869B2 (enExample)
AU (1) AU2002334889B2 (enExample)
CA (1) CA2461655A1 (enExample)
WO (1) WO2003031462A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522016A (ja) * 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするcDNA
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ATE469913T1 (de) * 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
US7541335B2 (en) * 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
CN1832752A (zh) * 2003-04-16 2006-09-13 耶鲁大学 治疗淀粉样蛋白斑相关性病症的nogo-受体拮抗剂
JP2007537985A (ja) * 2003-05-15 2007-12-27 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー 免疫調節ペプチド
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
CA2549000A1 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20080045926A1 (en) * 2004-01-30 2008-02-21 Relton Jane K Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists
US8039588B2 (en) * 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
PT1776136E (pt) * 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
CN101035803A (zh) * 2004-10-01 2007-09-12 耶鲁大学 Nogo-a多肽片段、变异nogo受体-1多肽、及其应用
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20070026463A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant Nogo-66 domain proteins
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
WO2007133746A2 (en) * 2006-05-15 2007-11-22 Biogen Idec Ma Inc. Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
EP2046828A2 (en) * 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
JP2010502623A (ja) * 2006-08-31 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Nogoレセプターポリペプチドの末梢投与に関する方法
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
JP2011505010A (ja) * 2007-11-28 2011-02-17 イェール ユニバーシティー 軸索成長を促進するNogo受容体結合低分子
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114197A2 (en) * 2008-03-13 2009-09-17 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0396719B1 (en) 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6962797B2 (en) * 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするcDNA
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
US6152155A (en) 1998-11-30 2000-11-28 Milligan; Lon Filter cleaning device
KR100529270B1 (ko) 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
IL143031A0 (en) 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1268506A4 (en) 1999-07-30 2004-07-28 Millennium Pharm Inc SECRET PROTEINS AND THEIR USE
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
EP1423427A2 (en) 2001-08-27 2004-06-02 Novartis AG Nogo receptor homologues and their use
WO2003035687A1 (en) 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20030113325A1 (en) * 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
CN1832752A (zh) * 2003-04-16 2006-09-13 耶鲁大学 治疗淀粉样蛋白斑相关性病症的nogo-受体拮抗剂
JP2007501612A (ja) 2003-08-07 2007-02-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Nogo受容体アンタゴニスト
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
US20080045926A1 (en) * 2004-01-30 2008-02-21 Relton Jane K Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists
WO2009114197A2 (en) 2008-03-13 2009-09-17 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury

Similar Documents

Publication Publication Date Title
JP2003519481A5 (enExample)
JP6807893B2 (ja) α−シヌクレインを認識するヒト化抗体
KR101681910B1 (ko) Rgm a 단백질에 대한 모노클로날 항체 및 이의 용도
ES2272093T5 (es) Composiciones y métodos para incrementar la mineralización de la substancia ósea
US9133272B2 (en) Bispecific binding agents
EP1181318B1 (en) Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
AU2018225493B2 (en) Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
JP2022543387A5 (enExample)
CA2872928C (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
HRP20180516T1 (hr) Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida
JP2009520691A5 (enExample)
EA015166B1 (ru) Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
JP2019527194A5 (enExample)
JP2008509658A5 (enExample)
RS57315B1 (sr) Humanizovana antitela koja prepoznaju alfa-sinuklein
KR20240046648A (ko) 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
KR20080111152A (ko) 염증성 질환의 치료를 위한 cxcl13 길항제 및 이의 용도
JP7449859B2 (ja) 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
JP2020517262A5 (enExample)
JP2008509152A5 (enExample)
JPH08504086A (ja) 背側組織作用因子及び組成物
JP2012508027A5 (enExample)
CA2750952A1 (en) Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
RU2007146455A (ru) Варианты эритропоэтина
JP2008539745A5 (enExample)